Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

September 11, 2023 Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …
News

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

September 7, 2023 Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …
News

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

September 4, 2023 Medical Communications AstraZeneca, CLL, China, Oncology, SLL

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …
News

Novo Nordisk launches Wegovy in the UK

September 4, 2023 Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …
News
hal-gatewood-_jbclosdsd4-unsplash

FDA approves new ADHD and BED generics

September 1, 2023 Medical Communications BED, FDA, Pharmacy, generic medicines

The US Food and Drug Administration (FDA) has announced that it has approved several first generics of Takeda’s Vyvanse (lisdexamfetamine …
News

First patient dosed in phase 1 study for chronic hepatitis B treatment

August 31, 2023 Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B

ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …
News
robina-weermeijer-ihfopazzjhm-unsplash_5

FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS

August 25, 2023 Medical Communications FDA, MS, Neurology, Sandoz

Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …
News

Tarsus Pharmaceuticals’ Xdemvy approved by FDA for treatment of Demodex blepharitis

August 25, 2023 Medical Communications Demodex blepharitis, FDA, Opthalmology, Tarsus Pharmaceuticals, eyedrops

Tarsus Pharmaceuticals has announced that the US Food and Drug Administration (FDA) approved its drug Xdemvy (lotillaner ophthalmic solution) 0.25% …
News
towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

Japan approves AstraZeneca’s Soliris for paediatric patients with gMG

August 24, 2023 Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris

AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use …
News
hal-gatewood-_jbclosdsd4-unsplash

FDA grants ODD to NXC-201 as multiple myeloma treatment

August 24, 2023 Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma

Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …
News
lungs

Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC

August 23, 2023 Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan

Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …
News

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

August 18, 2023 Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …
News

Iveric Bio’s marketing authorisation application for avacincaptad pegol accepted by EMA

August 18, 2023 Medical Communications CHMP, EMA, Iveric Bio, MAA, Opthalmology

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for avacincaptad pegol …
News

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

August 17, 2023 Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …
News

FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva

August 17, 2023 Medical Communications FDA, FOP, Musculo-skeletal disorder, Sohonos, ipsen

Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules as a retinoid indicated …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025